Dynavax Technologies (NASDAQ:DVAX) Upgraded at Wall Street Zen

Key Points

• Dynavax Technologies has been upgraded to a "buy" rating by Wall Street Zen, changing from a previous "hold" rating.
• JMP Securities increased the target price for DVAX shares from $31.00 to $32.00, while Goldman Sachs decreased theirs from $12.00 to $10.00, indicating mixed analyst sentiments.
• For the latest earnings report, Dynavax posted $0.14 EPS for the quarter, exceeding analysts' expectations and generating revenue of $95.44 million.

Wall Street Zen upgraded shares of Dynavax Technologies (NASDAQ:DVAX - Free Report) from a hold rating to a buy rating in a research report released on Saturday.

A number of other analysts have also recently weighed in on DVAX. JMP Securities upped their target price on shares of Dynavax Technologies from $31.00 to $32.00 and gave the company a "market outperform" rating in a research note on Friday. The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $24.33.

Dynavax Technologies Stock Performance

Shares of DVAX traded up $0.15 during trading hours on Friday, reaching $10.48. 1,700,978 shares of the company traded hands, compared to its average volume of 2,109,787. The stock's fifty day moving average is $10.50 and its 200 day moving average is $11.55. The stock has a market cap of $1.26 billion, a P/E ratio of -22.78 and a beta of 1.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. Dynavax Technologies has a 1-year low of $9.22 and a 1-year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.02. The business had revenue of $95.44 million during the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. Equities research analysts anticipate that Dynavax Technologies will post 0.32 earnings per share for the current fiscal year.

Institutional Trading of Dynavax Technologies

Large investors have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new stake in shares of Dynavax Technologies during the fourth quarter valued at approximately $192,000. O Shaughnessy Asset Management LLC acquired a new position in Dynavax Technologies in the fourth quarter valued at approximately $131,000. Franklin Resources Inc. lifted its holdings in Dynavax Technologies by 5.2% in the fourth quarter. Franklin Resources Inc. now owns 86,675 shares of the biopharmaceutical company's stock valued at $1,107,000 after buying an additional 4,260 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Dynavax Technologies by 20.9% in the fourth quarter. Envestnet Asset Management Inc. now owns 16,162 shares of the biopharmaceutical company's stock valued at $206,000 after buying an additional 2,796 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Dynavax Technologies by 96.5% in the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 1,169 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.